NYKODE THERAPEUTICS ASA: årsregnskap 2022 vs 2021
Shrank 75% on revenue, weaker earnings
approved 2023-04-18; registry 2023-07-12; journal 2023 562176
Summary
What changed
Comparing Årsregnskap 2022 with 2021 for NYKODE THERAPEUTICS ASA. Revenue 35.77m NOK → 9.03m NOK (-74.8%). Net result -8.60m NOK → -41.68m NOK. Equity 194.9k NOK → 158.83m NOK.
On the constructive side: equity strengthened; cash rose; current ratio back above 1×. Pressures included: revenue fell; operating result weakened; net result weakened.
Also worth watching: paid-in equity reduced; book investments changed. All figures are taken from the published annual accounts for NYKODE THERAPEUTICS ASA.
At a glance
Scorecard
What improved
-
↑
Equity strengthened
Book equity 194.9k NOK → 158.83m NOK (equity ratio 73.3% → 71.0%). Calculated
-
↑
Cash rose
Bank deposits 214.7k NOK → 205.70m NOK (+95696.4% YoY). Calculated
-
↑
Current ratio back above 1×
Current ratio 0.01× → 5.36×. Calculated
-
↑
Payroll decreased
Salary cost 14.46m NOK → 11.77m NOK (40% → 130% of revenue). Calculated
What deteriorated
-
↓
Revenue fell
Operating income / revenue moved from 35.77m NOK to 9.03m NOK (-74.8% YoY). Calculated
-
↓
Operating result weakened
Operating result -9.92m NOK → -52.15m NOK (op. margin -27.7% → -577.6%). Calculated
-
↓
Net result weakened
Net result -8.60m NOK → -41.68m NOK (net margin -24.0% → -461.6%). Calculated
Things to notice
-
·
Paid-in equity reduced
Paid-in equity fell 89.71m NOK → 83.66m NOK — check capital reduction, conversion, or reclassification. Interpretation
-
·
Book investments changed
Investment / intangible book value 941.0k NOK → 83.0k NOK. Reported fact